2026 Q1 -tulosraportti
UUTTA
2 päivää sitten
‧29 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 57 | - | - | ||
| 2 865 | - | - | ||
| 360 | - | - | ||
| 5 425 | - | - | ||
| 5 817 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·13 t sittenBioPorto (Investment case): Q1 2026, advancement on the three pillars central to the long-term potential https://www.inderes.dk/en/research/bioporto-investment-case-q1-2026-advancement-on-the-three-pillars-central-to-the-long-term-potential?utm_source=nordnet&utm_medium=integration·12 t sitten · MuokattuI can't help but wonder a bit that Michael Friis and Victor Skriver write that it is a concern that the patent expires in 2028. I know that Michael Friis has followed Bioporto for many years, by now, and he is well aware that when a copy test comes along, they must, first of all, at a minimum, go through the same process that Bioporto has gone through, and it is Bioporto's test that is the benchmark at the FDA. Secondly, the copycats must also convince all treatment centers that their copy test is better than Bioporto's NGAL test, and thirdly, the copy test must also be cheaper to use than the NGAL test for the treatment centers to start replacing the NGAL test with a copy test. The second thing I can't help but wonder about is whether the FDA will approve the test for adults? As I wrote, Michael Friis has followed Bioporto closely for many years, and therefore he knows well that KDIGO will issue a Grade 1 recommendation before the FDA manages to issue an approval for the NGAL test. Since no bomb has been dropped with evidence that the test does not work during the extended consultation period, for KDIGO would have announced it, the FDA will approve the NGAL test for adults. The FDA approval and KDIGO's recommendation bite their own tail, understood in the following way. KDIGO has looked at the FDA approval of the Pediatric test, and the FDA will look at KDIGO when they issue their recommendations. That being said, they do not compromise on their approvals and recommendations, but they are confirmed in that the NGAL test works. The only rational explanation for these two concerns that I can think of is that it is important for him to find some hairs in the soup, even if it is a mirage. The answer must be in the air, unfortunately, I don't think he reads this post.
·1 päivä sittenJust want to note that BP's increases historically have been driven by hysteria! These days/weeks/month(s) something "calmly" increasing is happening. And that, I think, is a sign of health. It doesn't jump by, for example, 75 øre. It seems to ground itself a bit à la two steps forward and one back. It looks calmer. It looks promising. Regards. Bagerbrød
·1 päivä sittenThe price finally seems to be turning around, as there are green %-s for the last 6 months, but there is still room for improvement. 2.0 must be the next target this year.·1 päivä sittenIt depends on when KDIGO comes out with a 1st degree recommendation for the NGAL test. Those of us who have kept the stock in our portfolio, and have bought at the bottom, we can just lean back and watch all those who only buy when the announcement is made public. Bioporto has announced that they have already acquired 4 new hospitals in Q1. The reason why these hospitals have already integrated the NGAL test in Q1 and not in Q4, (see CBs explanation in Webcast Q 4 2025) is due to KDIGO's draft and the various announcements before the hearing concluded. We know that FDA will approve the adult test, it's just a question of when.- ·2 päivää sittenKDIGO guidelines likely the next catalyst - Q1 review https://access.dnbcarnegie.com/publication/ef21af0f-6d31-42be-0550-08deb7025c09·1 päivä sittenProgression has formed a private club here on Nordnet, and there are 5 members. These are members who have all lost money on Bioporto, and they have made a pact to go together and commit a shit storm on Bioporto, on which they lost money, as revenge. According to themselves. You can figure out that progression is one member, and the others are those who follow along when a shit storm is to be carried out, either by liking each other's writings and/or they back each other up by contributing posts in the same style. As well as the posts I make, or others for that matter, if they are positive, they start coordinating their attack, as described above. They have not succeeded in making Bioporto go bankrupt, naturally, but they have succeeded in making so much noise that people have dumped their shares. But every time I and others come with negative news, there is silence from their side. I have long known that these attacks are coordinated, which I have claimed several times here on Nordnet social. Therefore, I have also actively looked for the smoking gun, and now I have found it and am sharing it here. Link to their closed club. https://www.nordnet.dk/forum/grupper/dk-progressionsklubben
- ·2 päivää sittenWhy has Bioporto perhaps chosen to deliver a "decimated" quarterly report, where many of the usual details are omitted? And why hasn't 3D commented yet? Has 3D perhaps not noticed it?·2 päivää sitten@Progression: Well, just that revenue increases while the loss decreases, and that is a good start to the year.·2 päivää sitten · MuokattuRevenue lands 6 % below the average quarterly sales in 2025. Has inflation been 4-5 % since 2025? Have sales on average fallen by 10 %? Is it the RSU sales that "drives" the business and not sales used in the healthcare sector? Is everything as it should be? The loss has become smaller vs Q1 25. Is there an explanation for the saving, has one sold fewer products at a higher price?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
UUTTA
2 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 t sittenBioPorto (Investment case): Q1 2026, advancement on the three pillars central to the long-term potential https://www.inderes.dk/en/research/bioporto-investment-case-q1-2026-advancement-on-the-three-pillars-central-to-the-long-term-potential?utm_source=nordnet&utm_medium=integration·12 t sitten · MuokattuI can't help but wonder a bit that Michael Friis and Victor Skriver write that it is a concern that the patent expires in 2028. I know that Michael Friis has followed Bioporto for many years, by now, and he is well aware that when a copy test comes along, they must, first of all, at a minimum, go through the same process that Bioporto has gone through, and it is Bioporto's test that is the benchmark at the FDA. Secondly, the copycats must also convince all treatment centers that their copy test is better than Bioporto's NGAL test, and thirdly, the copy test must also be cheaper to use than the NGAL test for the treatment centers to start replacing the NGAL test with a copy test. The second thing I can't help but wonder about is whether the FDA will approve the test for adults? As I wrote, Michael Friis has followed Bioporto closely for many years, and therefore he knows well that KDIGO will issue a Grade 1 recommendation before the FDA manages to issue an approval for the NGAL test. Since no bomb has been dropped with evidence that the test does not work during the extended consultation period, for KDIGO would have announced it, the FDA will approve the NGAL test for adults. The FDA approval and KDIGO's recommendation bite their own tail, understood in the following way. KDIGO has looked at the FDA approval of the Pediatric test, and the FDA will look at KDIGO when they issue their recommendations. That being said, they do not compromise on their approvals and recommendations, but they are confirmed in that the NGAL test works. The only rational explanation for these two concerns that I can think of is that it is important for him to find some hairs in the soup, even if it is a mirage. The answer must be in the air, unfortunately, I don't think he reads this post.
- ·1 päivä sittenJust want to note that BP's increases historically have been driven by hysteria! These days/weeks/month(s) something "calmly" increasing is happening. And that, I think, is a sign of health. It doesn't jump by, for example, 75 øre. It seems to ground itself a bit à la two steps forward and one back. It looks calmer. It looks promising. Regards. Bagerbrød
- ·1 päivä sittenThe price finally seems to be turning around, as there are green %-s for the last 6 months, but there is still room for improvement. 2.0 must be the next target this year.·1 päivä sittenIt depends on when KDIGO comes out with a 1st degree recommendation for the NGAL test. Those of us who have kept the stock in our portfolio, and have bought at the bottom, we can just lean back and watch all those who only buy when the announcement is made public. Bioporto has announced that they have already acquired 4 new hospitals in Q1. The reason why these hospitals have already integrated the NGAL test in Q1 and not in Q4, (see CBs explanation in Webcast Q 4 2025) is due to KDIGO's draft and the various announcements before the hearing concluded. We know that FDA will approve the adult test, it's just a question of when.
- ·2 päivää sittenKDIGO guidelines likely the next catalyst - Q1 review https://access.dnbcarnegie.com/publication/ef21af0f-6d31-42be-0550-08deb7025c09·1 päivä sittenProgression has formed a private club here on Nordnet, and there are 5 members. These are members who have all lost money on Bioporto, and they have made a pact to go together and commit a shit storm on Bioporto, on which they lost money, as revenge. According to themselves. You can figure out that progression is one member, and the others are those who follow along when a shit storm is to be carried out, either by liking each other's writings and/or they back each other up by contributing posts in the same style. As well as the posts I make, or others for that matter, if they are positive, they start coordinating their attack, as described above. They have not succeeded in making Bioporto go bankrupt, naturally, but they have succeeded in making so much noise that people have dumped their shares. But every time I and others come with negative news, there is silence from their side. I have long known that these attacks are coordinated, which I have claimed several times here on Nordnet social. Therefore, I have also actively looked for the smoking gun, and now I have found it and am sharing it here. Link to their closed club. https://www.nordnet.dk/forum/grupper/dk-progressionsklubben
- ·2 päivää sittenWhy has Bioporto perhaps chosen to deliver a "decimated" quarterly report, where many of the usual details are omitted? And why hasn't 3D commented yet? Has 3D perhaps not noticed it?·2 päivää sitten@Progression: Well, just that revenue increases while the loss decreases, and that is a good start to the year.·2 päivää sitten · MuokattuRevenue lands 6 % below the average quarterly sales in 2025. Has inflation been 4-5 % since 2025? Have sales on average fallen by 10 %? Is it the RSU sales that "drives" the business and not sales used in the healthcare sector? Is everything as it should be? The loss has become smaller vs Q1 25. Is there an explanation for the saving, has one sold fewer products at a higher price?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 57 | - | - | ||
| 2 865 | - | - | ||
| 360 | - | - | ||
| 5 425 | - | - | ||
| 5 817 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
UUTTA
2 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 t sittenBioPorto (Investment case): Q1 2026, advancement on the three pillars central to the long-term potential https://www.inderes.dk/en/research/bioporto-investment-case-q1-2026-advancement-on-the-three-pillars-central-to-the-long-term-potential?utm_source=nordnet&utm_medium=integration·12 t sitten · MuokattuI can't help but wonder a bit that Michael Friis and Victor Skriver write that it is a concern that the patent expires in 2028. I know that Michael Friis has followed Bioporto for many years, by now, and he is well aware that when a copy test comes along, they must, first of all, at a minimum, go through the same process that Bioporto has gone through, and it is Bioporto's test that is the benchmark at the FDA. Secondly, the copycats must also convince all treatment centers that their copy test is better than Bioporto's NGAL test, and thirdly, the copy test must also be cheaper to use than the NGAL test for the treatment centers to start replacing the NGAL test with a copy test. The second thing I can't help but wonder about is whether the FDA will approve the test for adults? As I wrote, Michael Friis has followed Bioporto closely for many years, and therefore he knows well that KDIGO will issue a Grade 1 recommendation before the FDA manages to issue an approval for the NGAL test. Since no bomb has been dropped with evidence that the test does not work during the extended consultation period, for KDIGO would have announced it, the FDA will approve the NGAL test for adults. The FDA approval and KDIGO's recommendation bite their own tail, understood in the following way. KDIGO has looked at the FDA approval of the Pediatric test, and the FDA will look at KDIGO when they issue their recommendations. That being said, they do not compromise on their approvals and recommendations, but they are confirmed in that the NGAL test works. The only rational explanation for these two concerns that I can think of is that it is important for him to find some hairs in the soup, even if it is a mirage. The answer must be in the air, unfortunately, I don't think he reads this post.
- ·1 päivä sittenJust want to note that BP's increases historically have been driven by hysteria! These days/weeks/month(s) something "calmly" increasing is happening. And that, I think, is a sign of health. It doesn't jump by, for example, 75 øre. It seems to ground itself a bit à la two steps forward and one back. It looks calmer. It looks promising. Regards. Bagerbrød
- ·1 päivä sittenThe price finally seems to be turning around, as there are green %-s for the last 6 months, but there is still room for improvement. 2.0 must be the next target this year.·1 päivä sittenIt depends on when KDIGO comes out with a 1st degree recommendation for the NGAL test. Those of us who have kept the stock in our portfolio, and have bought at the bottom, we can just lean back and watch all those who only buy when the announcement is made public. Bioporto has announced that they have already acquired 4 new hospitals in Q1. The reason why these hospitals have already integrated the NGAL test in Q1 and not in Q4, (see CBs explanation in Webcast Q 4 2025) is due to KDIGO's draft and the various announcements before the hearing concluded. We know that FDA will approve the adult test, it's just a question of when.
- ·2 päivää sittenKDIGO guidelines likely the next catalyst - Q1 review https://access.dnbcarnegie.com/publication/ef21af0f-6d31-42be-0550-08deb7025c09·1 päivä sittenProgression has formed a private club here on Nordnet, and there are 5 members. These are members who have all lost money on Bioporto, and they have made a pact to go together and commit a shit storm on Bioporto, on which they lost money, as revenge. According to themselves. You can figure out that progression is one member, and the others are those who follow along when a shit storm is to be carried out, either by liking each other's writings and/or they back each other up by contributing posts in the same style. As well as the posts I make, or others for that matter, if they are positive, they start coordinating their attack, as described above. They have not succeeded in making Bioporto go bankrupt, naturally, but they have succeeded in making so much noise that people have dumped their shares. But every time I and others come with negative news, there is silence from their side. I have long known that these attacks are coordinated, which I have claimed several times here on Nordnet social. Therefore, I have also actively looked for the smoking gun, and now I have found it and am sharing it here. Link to their closed club. https://www.nordnet.dk/forum/grupper/dk-progressionsklubben
- ·2 päivää sittenWhy has Bioporto perhaps chosen to deliver a "decimated" quarterly report, where many of the usual details are omitted? And why hasn't 3D commented yet? Has 3D perhaps not noticed it?·2 päivää sitten@Progression: Well, just that revenue increases while the loss decreases, and that is a good start to the year.·2 päivää sitten · MuokattuRevenue lands 6 % below the average quarterly sales in 2025. Has inflation been 4-5 % since 2025? Have sales on average fallen by 10 %? Is it the RSU sales that "drives" the business and not sales used in the healthcare sector? Is everything as it should be? The loss has become smaller vs Q1 25. Is there an explanation for the saving, has one sold fewer products at a higher price?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 57 | - | - | ||
| 2 865 | - | - | ||
| 360 | - | - | ||
| 5 425 | - | - | ||
| 5 817 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt